Mutations in DNA mismatch repair genes associated with Lynch syndrome (MLH1, MSH2, PMS2, MSH6, and EPCAM) have been associated with a modest increase in prostate cancer risk, particularly for MSH2 [2,3]. The gene discussed is MSH2; the disease is prostate carcinoma.